AlphaRose Therapeutics develops precision medicine for genetic diseases, focusing on autism and neuro-genetic disorders.
AlphaRose Therapeutics has raised $1.7M in total funding. The most recent round was Equity Crowdfunding. The last funding was announced in July 2025.
AlphaRose Therapeutics is headquartered in Austin, United States.
AlphaRose Therapeutics develops precision medicine for genetic diseases, focusing on autism and neuro-genetic disorders.
AlphaRose Therapeutics is at the Equity Crowdfunding stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AlphaRose Therapeutics — Funding & Investors." VCBacked, July 1, 2025, https://www.vcbacked.co/company/alpharose-therapeutics. Accessed October 8, 2026.
VCBacked. (2025). AlphaRose Therapeutics — Funding & Investors. Retrieved October 8, 2026, from https://www.vcbacked.co/company/alpharose-therapeutics
{{cite web |title=AlphaRose Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alpharose-therapeutics |website=VCBacked |access-date=October 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated